#5/I.D.S.

PATENT
Attorney Docket **054800-5003-02**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Roderic Dale *et al.***	)	
Application No. **10/076,597**	)	Group Art Unit: **1635**
Filed: **February 19, 2002**	)	Examiner: **Not Assigned**
For: **Therapeutic Antisense Phosphodiesterase Inhibitors**	)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(b)

Pursuant to 37 C.F.R. 1.56 and 1.97(b), Applicants brings to the attention of the Examiner the documents listed on the attached PTO-1449 and PTO-892. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe that a fee is due with the filing of this paper.

The present application is a divisional application of Application 09/364,626 (filed July 29, 1999) which is continuation-in-part of Application 09/223,586 (filed December 30, 1998). Information Disclosure Statements for Applications 09/364,626 and 09/223,586 were filed on June 10, 1999 and November 16, 1999 respectively. The attached PTO-1449 form lists all of the references cited in these Information Disclosure Statements and any references cited by the Examiner in these applications. The Examiner's attention is respectfully directed to the art of record in these prior applications and thus, no references are being submitted.

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute prior art. If the Examiner applies any one of the documents as prior art against any claim in the application, and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **December 12, 2002**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue
Washington, D.C. 20004
202-739-3000

Respectfully submitted
Morgan, Lewis & Bockius LLP



Robert Smyth
Registration No. 50,801

RECEIVED
DEC 13 2002
TECH CENTER 1600/2900

+

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket 054800-5003-02 | Application No. 10/076,597

Applicants: Roderic Dale *et al.* | Page 1 of 1

Filing Date: February 19, 2002 | Group Art Unit: 1635

U.S. PATENT DOCUMENTS

Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
	aa	5,851,784	12/22/1998	Owens *et al.*	435	19	12/22/1995

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Sub-Class	Translation
	ab	WO 94/15619	07/21/1994	PCT	CO7H	21/02	
	ac	WO 96/20281	07/04/1996	PCT	C12N	15/55	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	ad	Agrawal *et al.* (1988) Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus, Proc. Natl. Acad. Sci. USA 85:7079-7083
	ae	Baserga *et al.* (1992) Inhibition of cell cycle progression by antisense oligodeoxynucleotides, Ann. NY Acad. Sci. 660:64-69
	af	Beavo *et al.* (1990) Structure, Regulation and Drug Action, Multiple Phosphodiesterase Isozymes: Background, Nomenclature, and Implications, John Wiley & Sons, pp. 3-15
	ag	Branch (1998) A Good Antisense Molecule is Hard to Find, Trends Biochem. Sci. 23:45-50
	ah	Crooke (1993) Antisense Research and Applications, CRC Press
	ai	Crooke (1997) Antisense '97: a Roundtable on the State of the Industry, Nat. Biotechnol. 15:519-524
	aj	Grewe *et al.* (1982) Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness, J. Allergy Clin. Immunol. 70:452-457
	ak	Gura (1995) Antisense has Growing Pains, Science 270:575-577
	al	Hanifin *et al.* (1996) Type 4 phosphodiesterase inhibitors have clinical and invitro anti-inflammatory effects in atopic dermatitis, J. of Invest. Derm. 107:51-56
	am	Houslay *et al.* (1998) The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions, Adv. Pharmacol. 44:225-342
	an	Murray (ed.) Antisense RNA and DNA (Modern Cell Biology Series, Volume 11) (New York: John Wiley & Sons (1992))
	ao	Torphy *et al.* (1993) Drug News & Prospective 6:203-214
	ap	Wickstrom (1991) Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS, Wiley-Liss (1991
	aq	Zamecnik *et al.* (1986) Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA, Proc. Natl. Acad. Sci. USA 83:4143-4146

Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.